Dashboard
Manage Tickers

MCRBSeres Therapeutics, Inc.

Nasdaq serestherapeutics.com


$ 0.89 $ 0.02 (2.22 %)    

Monday, 26-Aug-2024 12:45:01 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.95 $ -5.98 (-1.25 %)
DIA $ 412.83 $ 1.00 (0.24 %)
SPY $ 559.35 $ -3.84 (-0.68 %)
TLT $ 98.25 $ -0.40 (-0.4 %)
GLD $ 232.59 $ -0.89 (-0.38 %)
$ 0.8707
$ 0.89
$ 0.89 x 100
-- x --
$ 0.88 - $ 0.94
$ 0.54 - $ 3.67
857,385
na
132.11M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-07-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 08-03-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 03-02-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 07-28-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 03-06-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-03-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 03-14-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

canaccord-genuity-maintains-buy-on-seres-therapeutics-maintains-10-price-target
Canaccord Genuity Maintains Buy on Seres T...
08/14/2024 13:43:33

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $10 price target.

chardan-capital-maintains-buy-on-seres-therapeutics-maintains-125-price-target
Chardan Capital Maintains Buy on Seres The...
08/14/2024 10:44:12

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $1.25 price target.

seres-therapeutics-q2-2024-gaap-eps-022-beats-027-estimate-712m-in-cash-and-cash-equivalents-that-is-expected-to-fund-operations-into-the-fourth-quarter-of-2025
Seres Therapeutics Q2 2024 GAAP EPS $(0.22...
08/13/2024 11:04:15

seres-therapeutics-has-signed-an-agreement-with-socit-des-produits-nestl-for-the-sale-of-its-vowst-business-to-nestl-health-science-seres-will-receive-capital-infusions-including-an-upfront-payment-a-prepaid-milestone-payment-and-an-equity-investment
Seres Therapeutics Has Signed An Agreement...
08/06/2024 11:58:38

In addition, Seres is due to receive installment payments in 2025, as well as potential future payments based on VOWST net sale...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
06/10/2024 16:31:08

why-gamestop-shares-are-trading-lower-by-over-22-here-are-other-stocks-moving-in-fridays-mid-day-session
Why GameStop Shares Are Trading Lower By O...
06/07/2024 17:07:30

oppenheimer-downgrades-seres-therapeutics-to-perform
Oppenheimer Downgrades Seres Therapeutics ...
06/07/2024 16:43:13

Oppenheimer analyst Jeff Jones downgrades Seres Therapeutics (NASDAQ:MCRB) from Outperform to Perform.

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
06/07/2024 16:31:05

canaccord-genuity-maintains-buy-on-seres-therapeutics-lowers-price-target-to-10
Canaccord Genuity Maintains Buy on Seres T...
06/07/2024 12:49:47

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and lowers the price target from...

seres-therapeutics-shares-are-lower-higher-after-the-company-entered-a-memorandum-of-understanding-with-nestl-health-science-for-the-sale-of-its-vowst-assets-the-stock-initially-traded-higher-but-it-has-since-reversed
Seres Therapeutics shares are lower higher...
06/06/2024 16:52:22

seres-therapeutics-shares-are-trading-higher-after-the-company-entered-a-memorandum-of-understanding-with-nestl-health-science-for-the-sale-of-its-vowst-assets
Seres Therapeutics shares are trading high...
06/06/2024 10:33:54

seres-therapeutics-entered-into-a-non-binding-memorandum-of-understanding-with-nestl-health-science-for-the-sale-of-seres-vowst-assets-under-the-terms-of-the-pending-agreement-seres-is-due-to-receive-capital-infusions-including-an-upfront-payment
Seres Therapeutics Entered Into A Non-bind...
06/06/2024 10:33:10

Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend i...

oppenheimer-maintains-outperform-on-seres-therapeutics-lowers-price-target-to-4
Oppenheimer Maintains Outperform on Seres ...
05/09/2024 16:50:17

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
05/09/2024 16:31:09

why-upstart-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Upstart Shares Are Trading Lower By Ar...
05/08/2024 17:38:56

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
05/08/2024 16:31:09

nasdaq-down-over-50-points-uber-posts-q1-loss
Nasdaq Down Over 50 Points; Uber Posts Q1 ...
05/08/2024 14:02:37

seres-therapeutics-q1-cash-and-cash-equivalents-of-1112m-is-expected-to-provide-cash-runway-into-q4-of-2024
Seres Therapeutics' Q1 Cash And Cash Equiv...
05/08/2024 11:07:10

seres-therapeutics-q1-2024-gaap-eps-027-beats-034-estimate
Seres Therapeutics Q1 2024 GAAP EPS $(0.27...
05/08/2024 11:05:53

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(...

seres-therapeutics-concludes-enrollment-in-cohort-2-of-phase-1b-trial-of-ser-155-in-allogeneic-hematopoietic-stem-cell-transplant-patients-clinical-data-readout-expected-end-of-q3-2024
Seres Therapeutics Concludes Enrollment In...
04/09/2024 11:11:45

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION